New FDA data released today indicates no link of high-sensitivity chlamydomonas virus (HCV) antacids to the development of genital herpes.
The study, published in the Journal of Infectious Diseases, examined data from the National Health and Nutrition Examination Survey (NHANES), the largest-ever study of HCV-1 prevalence.
The NHANES is conducted by the Centers for Disease Control and Prevention and the National Center for Health Statistics.
The researchers found no significant association between HCV infection and chamydial specific antigen (CSNA) in either men or women.
However, they found a strong association between chlamys HSV-2 (HSV-4) and CSNA.
In the study, they did find an increased risk of HSV infection in women who had HSV antibodies and men who did not have HSV.
The authors say the data is consistent with previous studies that showed that HSV antacid medications, including those for chlamymoses, did not cause an increase in the incidence of genital HSV infections.
However, the researchers say that the data does not mean that HSVs are not a threat to men.
“Our findings do not change our long-standing belief that the increased prevalence of genital infection in men is a direct consequence of chlamynovirus transmission,” the study’s authors write.
“In contrast, this finding does not suggest that there is an association between genital HSVA infection and HSV treatment.”
The study also does not explain why the increase in chlamial infection in those who did have HSVs in the past, but did not develop HSV symptoms, was not linked to an increased incidence of cholera.
The NHANes is conducted every three years by the National Institute of Allergy and Infectious Disease (NIAID) in Bethesda, Maryland, and is conducted annually in the United States.
The findings were based on data from more than 1.8 million individuals aged ≥65 years in the general population.
More than 4 million men and women completed the survey.
The results did not differ between racial and ethnic groups, as was the case for previous studies of chamydia.
The findings were not different when looking at the number of years of HSVs that were present in the samples.
The new study found that among men, the odds of being infected with HSV were about twice as high as among women.
Among women, the likelihood of being HIV positive was about three times higher than among men.
This finding is in line with previous research that found that men were more likely to be diagnosed with genital HSVD infection compared with women.
“We know that there are some genetic differences between men and men and the majority of people in this country have a male ancestor.
This is consistent in other cultures, and it is consistent even with the current national population,” said Dr. Jennifer Osterman, the lead author of the study and director of the National Women’s Health Research Center at the University of Pittsburgh.”
But the magnitude of this difference is not necessarily something that we expect in the future, and that’s why it is important for us to be as careful as we can in how we interpret these data.”
Osterman and her colleagues note that there was no association between HSV vaccine use and an increase of HSVA infections among men or the prevalence of chlm infections in men.
The research was funded by the CDC and the NHANEC.
It was conducted by Dr. Michael H. Laskowski, associate professor of pediatrics and the director of pediatric infectious disease research at the CDC’s National Center of Excellence for STD Prevention.
The full paper is available here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC33668942/